medigraphic.com

2015, Number 1

<< Back Next >>

Revista Cubana de Angiología y Cirugía Vascular 2015; 16 (1)

Control of the oral anticoagulant treatment in the older population with thromboembolic venous disease

Pantaleón BOS, Triana MME, Aldama FA, Valdés NY

Language: Spanish
References: 16
Page: 44-53
PDF size: 131.82 Kb.


ABSTRACT

Introduction: the scope of the oral anticoagulant treatment indications and the older age of patients in need of this treatment favored changes in its use and control without reducing its efficacy, so this is considered beneficial therapeutics for the elderly.
Objective: to describe the behavior of the control of oral anticoagulant treatment in the elderly population with thromboembolic venous disease.
Methods: a descriptive and analytical study of 76 patients (60 to 85 years) seen at the specialized service of the National Institute of Angiology and Vascular Surgery in two years. The level of control of anticoagulation was evaluated, the frequency of hemorrhagic events and other complications were determined.
Results: good control of the oral anticoagulant treatment was reached during the 2 year-period in younger than and over 60 years-old patients. No significant statistical difference was found when comparing the two groups. A higher index of slight hemorrhagic events was found in the study sample.
Conclusions: the control of the oral anticoagulant treatment in the older adult behaved similarly to that of the patient younger than 60 years, so the above mentioned treatment should be used in all the indications if the risk-benefit ratio is considered.


REFERENCES

  1. Hirsh J, Guyatt G, Albers GW, Harrington R, Schünemann HJ. Antithrombotic and thrombolytic therapy. Chest. 2008 [citado 20 Feb 2013];133:110S-2S. Disponible en: http://www.chestjournal.chestpubs.org/content/133/6_suppl/110S.full.html

  2. Robert-Ebadi H, Le Gal G, Righini M. Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging. 2009;4:165-77.

  3. Levi M. Epidemiology and management of bleeding in patients using vitamin K antagonists. J Thromb Haemost. 2009;7(Suppl 1):103-6.

  4. van der Besselaar AMHP, van der Meer FJM, Gerrits-Drabbe CW. Therapeutic control of oral anticoagulant treatment in the Netherlands. Am J Clin Pathol. 1988;90:685-90.

  5. Palareti G, Leati N, Coccheri S, Poggi M, Manotti C, D´Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996;348:423-8.

  6. Rosendaal FR, Cannegieter SC, van der Meer FJM, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemostas. 1993;69:236-9.

  7. Laínez-Sánchez LA, Villalobos-Masis C. Perfil clínico de los pacientes adultos mayores anticoagulados con warfarina del Hospital Nacional de Geriatría y Gerontología. Acta Med Costarric. 2011 [citado 6 Feb 2013];53:176-81. Disponible en: http://www.scielo.sa.cr/pdf/amc/v53n4/art04.pdf

  8. Frank M. Oral anticoagulation in the elderly -practical aspects and risk-benefit trade-off in atrial fibrillation. Praxis. 2010;31;99:429-35.

  9. Parra C. Importancia de la edad en la terapia de anticoagulación oral. Rev Chil Cardiol. 2009 [citado 14 Ene 2013];28:395-6. Disponible en: http://www.scielo.cl/pdf/rchcardiol/v28n4/art10.pdf

  10. Roller RE, Iglseder B, Dovjak P, Lechleitner M, Sommeregger U, Benvenuti-Falger U, et al. Oral anticoagulation and risk of bleeding in elderly patients - the aspect of polypharmacy. Wien Med Wochenschr. 2010;160:270-5.

  11. Pautas E, Gouin-Thibault I, Debray M, Gaussem P, Siguret V. Haemorrhagic complications of vitamin K antagonists in the elderly. Risk factors and management drugs. Aging. 2006;23:13-25.

  12. Fernández MA. Complicaciones de los AO. Complicaciones hemorrágicas: prevención y tratamiento. Complicaciones no hemorrágicas. En: Fernández MA, Sánchez A, editores. Anticoagulantes orales. Valencia: ToniBurguera; 2005. p. 101-22.

  13. Pantaleón O, Salazar Y, Triana ME, Aldama A, Garrido MJ, Alonso M. Introducción del control terapéutico en el seguimiento de pacientes tratados con anticoagulantes orales. Rev Cubana Invest Bioméd. 2009 [citado 14 Ene 2013]; 28:1-9. Disponible en: http://scielo.sld.cu/pdf/ibi/v28n1/ibi04109.pdf

  14. Forman DE, Goyette RE. Oral anticoagulation therapy for elderly patients with atrial fibrillation: Utility of bleeding risk covariates to better understand and moderate risks. Clin Appl Thromb Hemost. 2013 [citado 14 Ene 2013]. Disponible en: http://www.cat.sagepub.com/content/early/2013/06/07/1076029613492010

  15. Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges [review]. Nat Rev Cardiol. 2011;8:13-28.

  16. Wahast C, Badin G, Ferreira M C, Rejane E. Adhesión farmacológica al anticoagulante oral y factores que influyen en la estabilidad del índice de estandarización internacional. Rev Latino-Am Enfermagem. 2011 [citado 14 Ene 2013];19(1):8-15. Disponible en: http://www.scielo.br/pdf/rlae/v19n1/es_04.pdf




2020     |     www.medigraphic.com